文献速递急性肾损伤慢性肾脏病血液净化与透析

肾脏病中的临床药代动力学:合理设计给药方案的应用

Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-07-24

综述阐述肾脏病通过多种生理效应改变药代动力学,导致药物暴露变化和个体间差异;理解药代动力学概念有助于个体化设计给药方案,多数患者首剂与肾功能正常者相同,但脓毒症合并AKI使用抗感染药时可能需要较高负荷剂量后给予较低维持剂量。

要点

  • 肾脏病可导致药物清除下降,表观分布容积不变或增加,需个体化调整剂量。
  • AKI时肾功能动态变化使药物清除难以准确量化,CKD时清除下降较缓慢。
  • 肾脏替代治疗增加药物清除,程度取决于模式、时长、药物性质及给药时机。

核心结论

  • 肾脏病通过多种生理效应改变药代动力学,理解药代动力学原理有助于个体化设计给药方案。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 肾脏病时药物清除下降,表观分布容积不变或增加,变化存在个体差异且部分可量化。
  • AKI时肾功能动态变化使药物清除难以准确量化,CKD时清除下降较缓慢。
  • 肾脏替代治疗增加药物清除,程度取决于模式、时长、药物性质及给药时机。
  • 多数肾脏病患者首剂与肾功能正常者相同,但脓毒症合并AKI使用抗感染药时可能需较高负荷剂量后给予较低维持剂量。

临床怎么用

  • 对肾脏病患者应基于药代动力学原理个体化设计给药方案。
  • 多数患者首剂与肾功能正常者相同,但脓毒症合并AKI使用抗感染药时可考虑较高负荷剂量后较低维持剂量。
  • 使用肾脏替代治疗时需根据模式、时长、药物性质及给药时机评估药物清除变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A change in pharmacokinetics can alter drug exposure and predispose the patient to either over- or underdosing, potentially resulting in adverse drug reactions or therapeutic failure. Kidney disease is characterized by multiple physiologic effects, which induce clinically significant changes in pharmacokinetics. These vary between individuals and may be quantitated in certain instances. An understanding of pharmacokinetic concepts is, therefore, important for a rational approach to the design of drug dosing regimens for the delivery of personalized medical care. Whether kidney disease is acute or chronic, drug clearance decreases and the volume of distribution may remain unchanged or increase. AKI is defined by dynamic changes in kidney function, which complicates attempts to accurately quantify drug clearance. In contrast, changes in drug clearance progress more slowly with CKD. In general, kidney replacement therapies increase drug clearance, but the extent to which this occurs depends on the modality used and its duration, the drug's properties, and the timing of drug administration. However, the changes in drug handling associated with kidney disease are not isolated to reduced kidney clearance and an appreciation of the scale of potential derangements is important. In most instances, the first dose administered in patients with kidney disease is the same as in patients with normal kidney function. However, in some cases, a higher (loading) initial dose is given to rapidly achieve therapeutic concentrations, followed by a lower maintenance dose, as is well described when prescribing anti-infectives to patients with sepsis and AKI. This review provides an overview of how pharmacokinetic principles can be applied to patients with kidney disease to personalize dosage regimens. Patients with kidney disease are a vulnerable population and the increasing prevalence of kidney disease means that these considerations are important for all prescribers.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Roberts DM, Sevastos J, Carland JE, et al. Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens. Clin J Am Soc Nephrol. 2018. PMID: 30042221. doi:10.2215/CJN.05150418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。